Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 13;134(5):473-512.
doi: 10.1042/CS20190579.

A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure

Ryan P Ceddia  1 , Sheila Collins  1
Affiliations
Review

A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure

Ryan P Ceddia et al. Clin Sci (Lond). .

Abstract

With the ever-increasing burden of obesity and Type 2 diabetes, it is generally acknowledged that there remains a need for developing new therapeutics. One potential mechanism to combat obesity is to raise energy expenditure via increasing the amount of uncoupled respiration from the mitochondria-rich brown and beige adipocytes. With the recent appreciation of thermogenic adipocytes in humans, much effort is being made to elucidate the signaling pathways that regulate the browning of adipose tissue. In this review, we focus on the ligand-receptor signaling pathways that influence the cyclic nucleotides, cAMP and cGMP, in adipocytes. We chose to focus on G-protein-coupled receptor (GPCR), guanylyl cyclase and phosphodiesterase regulation of adipocytes because they are the targets of a large proportion of all currently available therapeutics. Furthermore, there is a large overlap in their signaling pathways, as signaling events that raise cAMP or cGMP generally increase adipocyte lipolysis and cause changes that are commonly referred to as browning: increasing mitochondrial biogenesis, uncoupling protein 1 (UCP1) expression and respiration.

Keywords: GPCRs; adipose; cyclic nucleotides; thermogenesis.

PubMed Disclaimer

Conflict of interest statement

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Figures

Figure 1.
Figure 1.. Catecholamine biosynthetic pathway and signaling
Epinephrine and norepinephrine (also called adrenaline and noradrenaline, respectively) are made from the amino acid tyrosine via the catecholamine biosynthetic pathway. Epinephrine and norepinephrine signal through nine GPCRs called the adrenoceptors. The α1 receptors are Gαq-coupled, α2 receptors are Gαi-coupled, and the β-receptors are Gαs-coupled. The α-receptors are activated by epinephrine and norepinephrine, with epinepherine having a lower potency than norepinephrine on the α2 receptors. For the β-receptors, in β1 norepinephrine is more potent than epinephrine, in β2 epinephrine is more potent than norepinephrine, and in β3 epinephrine and norepinephrine have similar potencies (adrenoceptors in the IUPHAR/BPS Guide to Pharmacology Database. Available from: https://doi.org/10.2218/gtopdb/F4/2019.4).
Figure 2.
Figure 2.. Sympathetic activation of adipocyte lipolysis and thermogenesis
Canonical activation of adipocyte lipolysis and thermogenesis occurs via the sympathetic nervous system. Sympathetic neurons release norepinephrine which activate β-adrenergic receptors on the adipocytes. Activation of these receptors turn on their associated G-proteins by causing the Gβγ (not shown) and Gαs subunits to dissociate. The Gαs subunit in turn augments adenylyl cyclase activity. The cAMP produced by adenylyl cyclase causes the regulatory subunits of PKA to dissociate from the catalytic subunits thereby liberating its activity. PKA phosphorylates and activates Hormone Sensitive Lipase (HSL) and other components of the lipolytic pathway. PKA also phosphorylates and activates p38 MAPK that leads to increased Ucp1 transcription and the expression of other pro-thermogenic genes.
Figure 3.
Figure 3.. Prostaglandin biosynthetic pathway and signaling
Prostaglandins are oxidative metabolites of arachidonic acid that are produced by cyclooxygenase (COX) enzymes. Arachidonic acid is liberated from the plasma membrane by phospholipase A2 (PLA2). COX converts arachidonic acid into the short lived PGH2 (not shown) which is converted into five primary bioactive prostanoids: PGE2, PGD2, PGF2α, PGI2 (prostacyclin) and TXA2 (thromboxane). These prostanoids act locally in an autocrine or paracrine manner. The local action of prostaglandins depends on activation of a family of GPCRs designated EP (for E prostanoid), DP, FP, IP and TP receptors, for the other prostaglandins, respectively.
Figure 4.
Figure 4.. Prostaglandin thermogenic signaling
PGE2−EP3 signaling is well known to be an important regulator of the increased thermogenesis that occurs during fever. In addition, recent studies have shown that prostaglandins are important regulators of adipocyte browning.
Figure 5.
Figure 5.. Guanylyl cyclase dependent activation of adipocyte lipolysis and thermogenesis
Activation of both soluble and membrane bound guanylyl cyclases in adipocytes increases intracellular cGMP concentrations. This leads to increased PKG activity, which phosphorylates and activates signaling pathways that cause increased lipolysis and thermogenic gene expression.
Figure 6.
Figure 6.. G-protein coupled receptors and cyclic nucleotide regulation of adipose tissue lipolysis and energy expenditure
Many hormones utilize GPCR-cAMP- or GC-cGMP-mediated pathways to regulate adipocyte lipolysis and energy expenditure. These pathways are inherently intertwined as the liberation of fatty acids by lipolysis supplies the fuel for the thermogenesis. It is interesting to note that so many of these hormones utilize the same downstream signaling mechanism. For this reason, treatment of adipocytes with these hormones produces (at least superficially) similar results.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fothergill E, Guo J, Howard L, Kerns JC, Knuth ND, Brychta R et al. (2016) Persistent metabolic adaptation 6 years after “The Biggest Loser” competition. Obesity (Silver Spring) 24, 1612–1619, 10.1002/oby.21538 - DOI - PMC - PubMed
    1. Laddu D, Dow C, Hingle M, Thomson C and Going S (2011) A review of evidence-based strategies to treat obesity in adults. Nutr. Clin. Pract.: Off. Pub. Am. Soc. Parent. Enteral. Nutr 26, 512–525, 10.1177/0884533611418335 - DOI
    1. Myers CA, Slack T, Martin CK, Broyles ST and Heymsfield SB (2015) Regional disparities in obesity prevalence in the United States: A spatial regime analysis. Obesity (Silver Spring) 23, 481–487, 10.1002/oby.20963 - DOI - PMC - PubMed
    1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al. (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384, 766–781, 10.1016/S0140-6736(14)60460-8 - DOI - PMC - PubMed
    1. Grundlingh J, Dargan PI, El-Zanfaly M and Wood DM (2011) 2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. J. Med. Toxicol.: Off. J. Am. College Med. Toxicol 7, 205–212, 10.1007/s13181-011-0162-6 - DOI

Publication types

Substances

-